# Boston Scientific Corp. BSX

NYSE; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000885725

**A/B**

**on the A/B boundary of 367 graded peers in healthcare**

rank 74 of 367; percentile 19.9; sampling error 2.5 points; lower is stronger

A B C D E

**A/B, the bull**




| Scoreboard | |
|---|---|
| **Profitability** | B/C<br>percentile 39.8 |
| **Solvency** | C<br>percentile 45.2 |
| **Growth and financing** | B<br>percentile 27.5 |
| **Reliability** | 0.94 AUC<br>filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| **Peer failure rate** | 0.52% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | over $2.67B assets<br>total assets $43.7B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress |
| **Inputs computable** | 12 of 14 |
| **Graded from** | filings received through Feb 17, 2026<br>271 days before the rescan; latest periodic filing 10-Q received Nov 2, 2026 |
| **Last close** | $44.35<br>2026-11-13; market equity $64.3B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 17, 2026*

of this Annual Report. The considerations and risks that follow are organized within relevant headings but may be relevant to other headings as well. Additional risks not presently known to us or that we currently deem immaterial may also adversely affect our business, financial condition, cash flows or results of operations. We face intense competition and may not be able to keep pace with the rapid technological changes in the medical devices industry or low-cost competitive offerings, which could have an adverse effect on our business, financial condition or results of operations. The medical device markets in which we participate are highly competitive.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*


| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 39.8** | | | | | | |
| Gross profitability | 31.7% | 32.3% | | 47.3 | 365 | 2025-12-31 |
| Return on invested capital | 9.7% | 9.3% | | 43.8 | 74 | 2025-12-31 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (4.0%) | (6.6%) | 66.3 | 799 | 2025-12-31 |
| Gross margin stability, five years | 0.3 pts | 2.8 pts | 1.7 | 242 | 2025-12-31 |
| **Solvency, sleeve percentile 45.2** | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | |
| *liabilities and a nearby cover-page share count are required at 2026-09-30* | | | | | |
| Altman Z double-prime | not computable | (0.31) | | | |
| *one or more required annual facts are missing* | | | | | |
| Net debt to EBITDA | 1.84x | 1.82x | 51.4 | 75 | 2025-12-31 |
| Interest coverage | 10.35x | (4.51x) | 6.5 | 78 | 2025-12-31 |
| Current ratio | 1.62x | 2.96x | 77.8 | 825 | 2025-12-31 |
| **Growth and financing, sleeve percentile 27.5** | | | | | |
| Revenue growth, three-year compound | 16.5% | 10.1% | 37.6 | 411 | 2025-12-31 |
| Free cash flow growth, three-year compound | 57.4% | 11.0% | 10.6 | 95 | 2025-12-31 |
| Reinvestment rate | 75.9% | 37.1% | 38.8 | 104 | 2025-12-31 |
| Asset growth, three years | 10.4% | 2.3% | 31.2 | 693 | 2025-12-31 |
| Net share issuance, one year | 0.5% | 2.4% | 19.0 | 627 | 2026-01-30 |

## Among 367 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 69 | Conmed Corp. (CNMD) | 18.6 | A/B | |
| 70 | Dexcom Inc. (DXCM) | 18.9 | A/B | fortress balance sheet |
| 71 | Adma Biologics, Inc. (ADMA) | 19.1 | A/B | late filer, fortress balance sheet |
| 72 | Orthofix Medical Inc. (OFIX) | 19.4 | A/B | |
| 73 | Merit Medical Systems Inc. (MMSI) | 19.7 | A/B | |
| 74 | Boston Scientific Corp. (BSX) | 19.9 | A/B | |
| 75 | Zoetis Inc. (ZTS) | 20.2 | A/B | |
| 76 | Ocular Therapeutix, Inc. (OCUL) | 20.5 | A/B | dilution |
| 77 | Alpha PRO Tech Ltd. (APT) | 20.8 | A/B | |
| 78 | Lineage Cell Therapeutics, Inc. (LCTX) | 21.0 | A/B | |
| 79 | Siga Technologies Inc. (SIGA) | 21.3 | A/B | fortress balance sheet |

## What the price implies

*at the 2026-11-13 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (56.7%) | (1.5%) | 12 |
| Distance from 52-week high | (57.8%) | (32.0%) | 23 |
| EBIT to enterprise value | 4.8% | (1.8%) | 80 |
| Free cash flow yield | 5.7% | (1.0%) | 85 |
| Book value to price | 0.40 | 0.29 | 59 |
| Sales to price | 0.31 | 0.29 | 51 |
| Composite equity issuance, five years | 2.3% | 19.1% | 30 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Relative strength against the sector, log excess return | (1.00) | (0.18) | 12 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score 7 of 9, period end 2025-12-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | pass |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $609.0M |
| Operating cash flow, four quarters | $4.2B |
| Months of runway | not finite |
| Days since last periodic filing | 13 (10-Q received Nov 2, 2026) |
| Median daily dollar volume, 63 sessions | $784.4M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $13.9B | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 2 | assets | us-gaap:Assets | $43.7B | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 3 | operating income | us-gaap:OperatingIncomeLoss | $3.6B | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 4 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $3.4B | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 5 | income tax | us-gaap:IncomeTaxExpenseBenefit | $493.0M | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 6 | total debt | us-gaap:LongTermDebtAndCapitalLeaseObligations | $11.1B | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 7 | book equity | us-gaap:StockholdersEquity | $24.2B | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 8 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $2.0B | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 9 | total debt | us-gaap:LongTermDebtAndCapitalLeaseObligations | $9.0B | 2024-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 10 | book equity | us-gaap:StockholdersEquity | $21.8B | 2024-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 11 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $414.0M | 2024-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 12 | net income | us-gaap:ProfitLoss | $2.9B | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $4.5B | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 14 | assets | us-gaap:Assets | $39.4B | 2024-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $20.1B | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 16 | gross profit | us-gaap:GrossProfit | $11.5B | 2024-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 17 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $16.7B | 2024-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 18 | gross profit | us-gaap:GrossProfit | $9.9B | 2023-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 19 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $14.2B | 2023-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 20 | gross profit | us-gaap:GrossProfit | $8.7B | 2022-12-31 | 2025-02-18 | 10-K | 25-000011 |
| 21 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $12.7B | 2022-12-31 | 2025-02-18 | 10-K | 25-000011 |
| 22 | gross profit | us-gaap:GrossProfit | $8.2B | 2021-12-31 | 2024-02-20 | 10-K | 24-000017 |
| 23 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $11.9B | 2021-12-31 | 2024-02-20 | 10-K | 24-000017 |
| 24 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $1.4B | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 25 | interest expense | us-gaap:InterestExpense | $349.0M | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 26 | current assets | us-gaap:AssetsCurrent | $8.8B | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 27 | current liabilities | us-gaap:LiabilitiesCurrent | $5.4B | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 28 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $876.0M | 2025-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 29 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $3.4B | 2024-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 30 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $790.0M | 2024-12-31 | 2026-02-17 | 10-K | 26-000010 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 31 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $2.5B | 2023-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 32 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $711.0M | 2023-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 33 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $1.5B | 2022-12-31 | 2025-02-18 | 10-K | 25-000011 |
| 34 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $588.0M | 2022-12-31 | 2025-02-18 | 10-K | 25-000011 |
| 35 | current assets | us-gaap:AssetsCurrent | $6.9B | 2024-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 36 | current liabilities | us-gaap:LiabilitiesCurrent | $6.4B | 2024-12-31 | 2026-02-17 | 10-K | 26-000010 |
| 37 | assets | us-gaap:Assets | $35.1B | 2023-12-31 | 2025-02-18 | 10-K | 25-000011 |
| 38 | assets | us-gaap:Assets | $32.5B | 2022-12-31 | 2024-02-20 | 10-K | 24-000017 |
| 39 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 1,483,885,456 | 2026-01-30 | 2026-02-17 | 10-K | 26-000010 |
| 40 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 1,475,778,104 | 2025-01-31 | 2025-02-18 | 10-K | 25-000011 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.